Tema Oncology ETF (CANC)

The Tema Oncology ETF owns a basket of companies working on cancer. It holds drug makers. It holds companies that make machines to scan you or treat you. It holds labs that run tests. Every company in the fund makes money partly or mostly from fighting cancer.

Why bundle cancer companies together

A regular healthcare fund owns hospitals, insurance companies, and drugmakers for every disease. Oncology is different. It is one disease but enormous. Millions of people get cancer every year. They need expensive drugs. They need scans and surgery. They need genetic tests and follow-up care for years. Companies that figure out how to treat cancer well can charge real money, because patients will pay, and so will governments and insurance companies.

The idea behind CANC is simple: instead of picking one cancer company and hoping you choose the winner, own many. Own drugmakers and device companies and diagnostic labs all at once. If you are right that cancer care will grow, you win with the whole basket. If one company fails in a trial, the others carry the load.

What you actually own

CANC starts with a rule: which publicly listed companies make real money from cancer. It includes huge pharmaceutical names like Bristol Myers Squibb and Merck, which sell oncology drugs alongside other medicines. It includes smaller biotech companies like Exact Sciences that make cancer tests. It includes makers of radiation therapy machines and robotic surgery systems. It includes clinical trial networks. It includes companies you have never heard of but that supply hospitals and clinics with cancer gear.

The holdings list changes. Companies get added if their cancer business grows large enough. Companies get dropped if their cancer revenue shrinks. The fund publishes what it owns, so you can see the list at any time.

The upside of focus

You do not have to pick which oncology company will win. You own them all — or at least, the ones the rules say are big enough to matter. That cuts your risk if one company’s new drug fails or if a regulator rejects an application.

You also get less overlap with the overall market. A healthcare fund is more tied to the economy and interest rates and general stock sentiment. An oncology fund is narrower. It cares about one thing: whether cancer treatment is advancing and people will pay for it. In years when cancer care is hot, oncology stocks should beat the market. In years when biotech is cold, they might lag.

The downside of narrowness

Because CANC is narrow, it swings harder. If the FDA approves three breakthrough cancer drugs in one month, CANC might jump up fast. If a trial fails or a government tries to cut drug prices, CANC might drop hard. It is more volatile than owning the whole healthcare sector.

There is also the crowd problem. When a lot of people decide cancer care is the future and buy CANC, the prices of the stocks inside go up. That raises the cost for new buyers. It makes future returns smaller.

And oncology is mostly pharma and biotech. Those are the industries where cancer treatment happens. So CANC is really a concentrated bet on whether pharma and biotech will do well. If those sectors fall out of favor, CANC falls with them.

Cost and trading

CANC charges a fee — typically in the mid single digits as a percentage per year — because it needs to screen companies and keep the oncology theme alive. The fund itself is easy to buy and sell on a stock exchange. But some of the companies inside it (small biotech firms) are hard to trade, which can make the fund harder to sell quickly if you need out.

What to watch

Before you buy, look at the fund’s current holdings. See which names are in there. Do some of them look like they are in trouble? Read their latest earnings reports. Check their drug pipeline. Watch the news. When the FDA approves a cancer drug or rejects one, the whole fund can move. Remember: many early-stage cancer companies never get a drug to market. That risk lives inside CANC.